During cancer development, the TGF‐β signaling pathway plays crucial roles in the different stages of cancer[10]; m6A mRNA modification also affects tumor progression through various mechanisms, including liquid–liquid phase separation.[36] SMAD2/3 promotes the binding of the m6A methyltransferase complex to a subset of transcripts involved in early cell fate decisions.[15] However, little is known regarding the relationship between TGF‐β and m6A modification in HCC development. The gene discussed is SMAD2; the disease is hepatocellular carcinoma.